Ya-Chao Wang1, Francesca Galeffi2, Wei Wang3, Xuan Li1, Liping Lu1, Huaxin Sheng1, Ulrike Hoffmann1, Dennis A Turner4, Wei Yang5. 1. Center for Perioperative Organ Protection, Department of Anesthesiology, Duke University Medical Center, Durham, NC, USA. 2. Research and Surgery Services, Durham VAMC, Durham, NC, USA. 3. Center for Perioperative Organ Protection, Department of Anesthesiology, Duke University Medical Center, Durham, NC, USA; Department of Anesthesiology, Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China. 4. Research and Surgery Services, Durham VAMC, Durham, NC, USA; Departments of Neurosurgery, Neurobiology and Biomedical Engineering, Duke University Medical Center, Durham, NC, USA. 5. Center for Perioperative Organ Protection, Department of Anesthesiology, Duke University Medical Center, Durham, NC, USA. Electronic address: wei.yang@duke.edu.
Abstract
BACKGROUND AND PURPOSE: Ischemic stroke significantly perturbs neuronal homeostasis leading to a cascade of pathologic events causing brain damage. In this study, we assessed acute stroke outcome after chemogenetic inhibition of forebrain excitatory neuronal activity. METHODS: We generated hM4Di-TG transgenic mice expressing the inhibitory hM4Di, a Designer Receptors Exclusively Activated by Designer Drugs (DREADD)-based chemogenetic receptor, in forebrain excitatory neurons. Clozapine-N-oxide (CNO) was used to activate hM4Di DREADD. Ischemic stroke was induced by transient occlusion of the middle cerebral artery. Neurologic function and infarct volumes were evaluated. Excitatory neuronal suppression in the hM4Di-TG mouse forebrain was assessed electrophysiologically in vitro and in vivo, based on evoked synaptic responses, and in vivo based on occurrence of potassium-induced cortical spreading depolarizations. RESULTS: Detailed characterization of hM4Di-TG mice confirmed that evoked synaptic responses in both in vitro hippocampal slices and in vivo motor cortex were significantly reduced after CNO-mediated activation of the inhibitory hM4Di DREADD. Further, CNO treatment had no obvious effects on physiology and motor function in either control or hM4Di-TG mice. Importantly, hM4Di-TG mice treated with CNO at either 10 min before ischemia or 30 min after reperfusion exhibited significantly improved neurologic function and smaller infarct volumes compared to CNO-treated control mice. Mechanistically, we showed that potassium-induced cortical spreading depression episodes were inhibited, including frequency and duration of DC shift, in CNO-treated hM4Di-TG mice. CONCLUSIONS: Our data demonstrate that acute inhibition of a subset of excitatory neurons after ischemic stroke can prevent brain injury and improve functional outcome. This study, together with the previous work in optogenetic neuronal modulation during the chronic phase of stroke, supports the notion that targeting neuronal activity is a promising strategy in stroke therapy.
BACKGROUND AND PURPOSE:Ischemic stroke significantly perturbs neuronal homeostasis leading to a cascade of pathologic events causing brain damage. In this study, we assessed acute stroke outcome after chemogenetic inhibition of forebrain excitatory neuronal activity. METHODS: We generated hM4Di-TGtransgenic mice expressing the inhibitory hM4Di, a Designer Receptors Exclusively Activated by Designer Drugs (DREADD)-based chemogenetic receptor, in forebrain excitatory neurons. Clozapine-N-oxide (CNO) was used to activate hM4Di DREADD. Ischemic stroke was induced by transient occlusion of the middle cerebral artery. Neurologic function and infarct volumes were evaluated. Excitatory neuronal suppression in the hM4Di-TGmouse forebrain was assessed electrophysiologically in vitro and in vivo, based on evoked synaptic responses, and in vivo based on occurrence of potassium-induced cortical spreading depolarizations. RESULTS: Detailed characterization of hM4Di-TGmice confirmed that evoked synaptic responses in both in vitro hippocampal slices and in vivo motor cortex were significantly reduced after CNO-mediated activation of the inhibitory hM4Di DREADD. Further, CNO treatment had no obvious effects on physiology and motor function in either control or hM4Di-TGmice. Importantly, hM4Di-TGmice treated with CNO at either 10 min before ischemia or 30 min after reperfusion exhibited significantly improved neurologic function and smaller infarct volumes compared to CNO-treated control mice. Mechanistically, we showed that potassium-induced cortical spreading depression episodes were inhibited, including frequency and duration of DC shift, in CNO-treated hM4Di-TGmice. CONCLUSIONS: Our data demonstrate that acute inhibition of a subset of excitatory neurons after ischemic stroke can prevent brain injury and improve functional outcome. This study, together with the previous work in optogenetic neuronal modulation during the chronic phase of stroke, supports the notion that targeting neuronal activity is a promising strategy in stroke therapy.
Authors: Thijs Houben; Inge Cm Loonen; Serapio M Baca; Maarten Schenke; Johanna H Meijer; Michel D Ferrari; Gisela M Terwindt; Rob A Voskuyl; Andrew Charles; Arn Mjm van den Maagdenberg; Else A Tolner Journal: J Cereb Blood Flow Metab Date: 2016-01-01 Impact factor: 6.200
Authors: Jed A Hartings; C William Shuttleworth; Sergei A Kirov; Cenk Ayata; Jason M Hinzman; Brandon Foreman; R David Andrew; Martyn G Boutelle; K C Brennan; Andrew P Carlson; Markus A Dahlem; Christoph Drenckhahn; Christian Dohmen; Martin Fabricius; Eszter Farkas; Delphine Feuerstein; Rudolf Graf; Raimund Helbok; Martin Lauritzen; Sebastian Major; Ana I Oliveira-Ferreira; Frank Richter; Eric S Rosenthal; Oliver W Sakowitz; Renán Sánchez-Porras; Edgar Santos; Michael Schöll; Anthony J Strong; Anja Urbach; M Brandon Westover; Maren Kl Winkler; Otto W Witte; Johannes Woitzik; Jens P Dreier Journal: J Cereb Blood Flow Metab Date: 2016-01-01 Impact factor: 6.200
Authors: Hajime Nakamura; Anthony J Strong; Christian Dohmen; Oliver W Sakowitz; Stefan Vollmar; Michael Sué; Lutz Kracht; Parastoo Hashemi; Robin Bhatia; Toshiki Yoshimine; Jens P Dreier; Andrew K Dunn; Rudolf Graf Journal: Brain Date: 2010-05-26 Impact factor: 13.501